Bausch & Lomb and ophthalmic medical device company AcuFocus announced that a subsidiary of Bausch & Lomb has acquired AcuFocus pursuant to a merger transaction with AcuFocus’ parent company. AcuFocus has brought innovative small-diaphragm intraocular technology to the industry to address a variety of unmet needs in eye care, including the IC-8® Apthera™ intraocular lens, the first and only small-aperture, non-toric extended depth of focus lens approved by the U.S. Food and Drug Administration in July 2022 for certain cataract patients with corneal astigmatism up to 1.5 diopters who also wish to address presbyopia. Joseph C. Papa, Ceo of Bausch & Lomb, said, “Cataract is the leading cause of global blindness, accounting for approximately forty-five percent of the more than 33 million global cases of blindness in adults aged 50 and older. We believe the IC-8® Apthera™ intraocular lens will strengthen our surgical portfolio.” Al Waterhouse, President and Ceo of AcuFocus, said, “Bausch & Lomb is a legendary brand in eye care. With Bausch & Lomb’s recognized commercial expertise, we believe Bausch & Lomb is ideally positioned to educate physicians about the IC-8® Apthera™ intraocular lens and give more cataract patients access to this new intraocular lens.”

March 2023